Page 132 - Read Online

Cao et al. J Transl Genet Genom 2019;3:4. I https://doi.org/10.20517/jtgg.2018.16 Page 11 of 12

immunity against intestinal pathogens. Nat Genet 2014;46:1187-96.
47. Li M, Foo JN, Wang JQ, Low HQ, Tang XQ, et al. Identification of new susceptibility loci for IgA nephropathy in Han Chinese. Nat
Commun 2015;6:7270.
48. Nie R, Cheng G, Zhang J, Dong Y, Wang C, et al. The association of rs1047763 and rs1008898 of C1GALT1 with IgA nephropathy risk: a
global meta-analysis. Monoclon Antib Immunodiagn Immunother 2017;36:95-103.
49. Gharavi AG, Kiryluk K, Choi M, Li Y, Hou P, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat
Genet 2011;43:321-7.
50. Jullien P, Laurent B, Claisse G, Masson I, Dinic M, et al. Deletion variants of CFHR1 and CFHR3 associate with mesangial immune
deposits but not with progression of IgA nephropathy. J Am Soc Nephrol 2018;29:661-9.
51. Zhai YL, Meng SJ, Zhu L, Shi SF, Wang SX, et al. Rare variants in the complement factor H-related protein 5 gene contribute to genetic
susceptibility to IgA nephropathy. J Am Soc Nephrol 2016;27:2894-905.
52. Qi YY, Zhou XJ, Cheng FJ, Hou P, Zhu L, et al. DEFA gene variants associated with IgA nephropathy in a Chinese population. Genes
Immun 2015;16:231-7.
53. Feehally J, Farrall M, Boland A, Gale DP, Gut I, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am
Soc Nephrol 2010;21:1791-7.
54. Milillo A, La Carpia F, Costanzi S, D’Urbano V, Martini M, et al. A SPRY2 mutation leading to MAPK/ERK pathway inhibition is
associated with an autosomal dominant form of IgA nephropathy. Eur J Hum Genet 2015;23:1673-8.
55. Gale DP, Molyneux K, Wimbury D, Higgins P, Levine AP, et al. Galactosylation of IgA1 is associated with common variation in C1GALT1.
J Am Soc Nephrol 2017;28:2158-66.
56. Zhong Z, Feng SZ, Xu RC, Li ZJ, Huang FX, et al. Association of TNFSF13 polymorphisms with IgA nephropathy in a Chinese Han
population. J Gene Med 2017; doi: 10.1002/jgm.2966.
57. Maillard N, Wyatt RJ, Julian BA, Kiryluk K, Gharavi A, et al. Current understanding of the role of complement in IgA nephropathy. J Am
Soc Nephrol 2015;26:1503-12.
58. Cox SN, Pesce F, El-Sayed Moustafa JS, Sallustio F, Serino G, et al. Multiple rare genetic variants co-segregating with familial IgA
nephropathy all act within a single immune-related network. J Intern Med 2017;281:189-205.
59. Xue JL, Eggers PW, Agodoa LY, Foley RN, Collins AJ. Longitudinal study of racial and ethnic differences in developing end-stage renal
disease among aged medicare beneficiaries. J Am Soc Nephrol 2007;18:1299-306.
60. Kopp JB, Smith MW, Nelson GW, Johnson RC, Freedman BI, et al. MYH9 is a major-effect risk gene for focal segmental
glomerulosclerosis. Nat Genet 2008;40:1175-84.
61. Tzur S, Rosset S, Shemer R, Yudkovsky G, Selig S, et al. Missense mutations in the APOL1 gene are highly associated with end stage
kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010;128:345-50.
62. Limou S, Nelson GW, Kopp JB, Winkler CA. APOL1 kidney risk alleles: population genetics and disease associations. Adv Chronic Kidney
Dis 2014;21:426-33.
63. Genovese G, Friedman DJ, Ross MD, Lecordier L, Uzureau P, et al. Association of trypanolytic ApoL1 variants with kidney disease in
African Americans. Science 2010;329:841-5.
64. Limou S, Dummer PD, Nelson GW, Kopp JB, Winkler CA. APOL1 toxin, innate immunity, and kidney injury. Kidney Int 2015;88:28-34.
65. Parsa A, Kao WH, Xie D, Astor BC, Li M, et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med
2013;369:2183-96.
66. Larsen CP, Beggs ML, Saeed M, Walker PD. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated
collapsing glomerulopathy. J Am Soc Nephrol 2013;24:722-5.
67. Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, et al. Apolipoprotein L1 gene variants associate with hypertension-
attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013;83:114-20.
68. Kopp JB, Nelson GW, Sampath K, Johnson RC, Genovese G, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-
associated nephropathy. J Am Soc Nephrol 2011;22:2129-37.
69. Papeta N, Kiryluk K, Patel A, Sterken R, Kacak N, et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J
Am Soc Nephrol 2011;22:1991-6.
70. Freedman BI, Pastan SO, Israni AK, Schladt D, Julian BA, et al. APOL1 genotype and kidney transplantation outcomes from deceased
African American donors. Transplantation 2016;100:194-202.
71. Lee BT, Kumar V, Williams TA, Abdi R, Bernhardy A, et al. The APOL1 genotype of African American kidney transplant recipients does
not impact 5-year allograft survival. Am J Transplant 2012;12:1924-8.
72. Chandraker A. The real world impact of APOL1 variants on kidney transplantation. Transplantation 2016;100:16-7.
73. Cooper ME. Diabetes: treating diabetic nephropathy-still an unresolved issue. Nat Rev Endocrinol 2012;8:515-6.
74. Sandholm N Van Zuydam N, Ahlqvist E, Juliusdottir T, Deshmukh HA, et al. The genetic landscape of renal complications in type 1
diabetes. J Am Soc Nephrol 2017;28:557-74.
75. Teumer A, Tin A, Sorice R, Gorski M, Yeo NC, et al. Genome-wide association studies identify genetic loci associated with albuminuria in
diabetes. Diabetes 2016;65:803-17.
76. Pezzolesi MG, Poznik GD, Skupien J, Smiles AM, Mychaleckyj JC, et al. An intergenic region on chromosome 13q33.3 is associated with
the susceptibility to kidney disease in type 1 and 2 diabetes. Kidney Int 2011;80:105-11.
77. Sandholm N, McKnight AJ, Salem RM, Brennan EP, Forsblom C, et al. Chromosome 2q31.1 associates with ESRD in women with type 1
diabetes. J Am Soc Nephrol2013;24:1537-43.